RGI-7000

also known as KRN7000 · RGI-2001 · (2S, 3S, 4R)-1-O-(a-D-galactopyranosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol · .alpha.-galcer · a-GalCer · AGL-582 · Alpha-galactosylceramide · BPC-2001

Small molecule targets CD1D via activation

Developed for: acute graft versus host disease · graft versus host disease · chronic hepatitis B virus infection · chronic hepatitis C virus infection · lung cancer
Investigated by: Regimmune Corporation · Foundation for Liver Research · BioPhoenix Co., Ltd. · European Organisation for Research and Treatment of Cancer - EORTC · Kyowa Kirin, Inc. · Zachariah Michael DeFilipp

Trials 7 · a red edge is where a trial was stopped

today NCT07246031 · Ph 2 NCT04473911 · Ph 1 NCT04014790 · Ph 2 NCT01379209 · Ph 1/2 NCT00352235 · Ph 1/2 NCT00363155 · Ph 1/2 NCT00003985 · Ph 1

1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT04473911	Aug 2020 → Oct 2023	Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, bone marrow failure syndrome +3	Zachariah Michael DeFilipp	Completed	No outcome recorded
Phase 1	NCT00003985	Sep 1998 → ?	lung cancer	European Organisation for Research and Treatment of Cancer - EORTC	Withdrawn	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT01379209	Sep 2011 → Jun 2015	graft versus host disease	Regimmune Corporation	Completed	No outcome recorded
Phase 1/2	NCT00352235	Aug 2003 → May 2005	chronic hepatitis C virus infection	Foundation for Liver Research	Completed	No outcome recorded
Phase 1/2	NCT00363155	Mar 2003 → Jul 2006	chronic hepatitis B virus infection	Foundation for Liver Research	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT07246031	Oct 2025 → Nov 2027 expected	acute graft versus host disease, chronic graft versus host disease	BioPhoenix Co., Ltd.	Recruiting	No outcome recorded
Phase 2	NCT04014790	Nov 2019 → Jul 2022	acute graft versus host disease	Regimmune Corporation	Completed	No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

Field	Value	Cited text
Known as	RGI-7000	ChEMBL registry synonym — accepted as the source's own label CHEMBL384200 ↗
Known as	(2S, 3S, 4R)-1-O-(a-D-galactopyranosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol	“Patients with chronic hepatitis C who met the inclusion criteria are assigned to receive a-GalCer (KRN7000 ((2S, 3S,...” NCT00352235 ↗
Known as	.alpha.-galcer	ChEMBL registry synonym — accepted as the source's own label CHEMBL384200 ↗
Known as	a-GalCer	“Patients with chronic hepatitis C who met the inclusion criteria are assigned to receive a-GalCer (KRN7000 ((2S, 3S,...” NCT00352235 ↗
Known as	AGL-582	ChEMBL registry synonym — accepted as the source's own label CHEMBL384200 ↗
Known as	Alpha-galactosylceramide	ChEMBL registry synonym — accepted as the source's own label CHEMBL384200 ↗
Known as	BPC-2001	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07246031 ↗
Known as	KRN7000	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00352235 ↗ 2 NCT00363155 ↗ NCT00003985 ↗
Known as	RGI-2001	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01379209 ↗ 2 NCT04014790 ↗ NCT04473911 ↗
Action	Inhibit	“KRN7000 is reported to inhibit HBV replication in HBV transgenic mice.” NCT00363155 ↗
Modality	Other / unclassified	“RGI-2001, a glycolipid” PMID 40680268 ↗ Oct 2025
Modality	Small molecule	— CHEMBL384200 ↗
Route	Intravenous	“by slow intravenous injection” NCT00003985 ↗
Target	CD1D	“binds CD1d receptor” PMID 40680268 ↗ Oct 2025